EUCTR2005-000842-35-IT进行中（未招募）不适用
A Randomised, Double-Blind, Multinational, Multicenter, Placebo-controlled Parallel Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg o.d. and 150 mg o.d.) Given During 12 weeks in Comparison with Placebo in the Treatment of Subjects with Lamellar Ichthyosis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 98
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal OsteoporosisMedDRA version: 20.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2020-005548-48-DETeva Branded Pharmaceutical Products R&D, Inc.326
进行中（未招募）
1 期
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal OsteoporosisPostmenopausal OsteoporosisEUCTR2020-005548-48-CZTeva Branded Pharmaceutical Products R&D, Inc.326
进行中（未招募）
1 期
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal OsteoporosisPostmenopausal OsteoporosisEUCTR2020-005548-48-BGTeva Branded Pharmaceutical Products R&D, Inc.326
进行中（未招募）
1 期
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal OsteoporosisPostmenopausal OsteoporosisEUCTR2020-005548-48-HUTeva Branded Pharmaceutical Products R&D, Inc.326
进行中（未招募）
1 期
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal OsteoporosisMedDRA version: 20.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2020-005548-48-SKTeva Branded Pharmaceutical Products R&D, Inc.326